Discover our portfolio

 

Activity

Created by Truffle, Vexim has developed and commercialized a revolutionary spinal implant for the treatment of vertebral fractures through minimal invasive surgery.
In 2017, 6 years after the commercial launch of its SpineJack, Vexim registered sales of € 22M and 10% market share in Europe.

The company was sold in 2017 to Stryker for a total amount of € 180M.
In September 2018, the product received the FDA approval for marketing in the US.

Contact Truffle Capital

7 + 5 =

BUREAU

5 Rue de la Baume, 75008 Paris, France
Tel: +33 1 82 28 46 00

EMAIL

contact@truffle.com

NOS SITES

Truffle Capital

Truffle Capital

5 Rue de la Baume, 75008 Paris, France
Tel: 01 82 28 46 00
Email: contact@truffle.com

© 2019 Truffle Capital

 

 

Truffle Capital 2019

Tous droits réservés
Mentions légales
Informations réglementaires

 

 

Réseaux sociaux